Brokerages expect AxoGen, Inc. (NASDAQ:AXGN) to report $28.65 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for AxoGen’s earnings. The lowest sales estimate is $28.00 million and the highest is $29.30 million. AxoGen reported sales of $24.26 million in the same quarter last year, which suggests a positive year-over-year growth rate of 18.1%. The business is expected to announce its next earnings report after the market closes on Wednesday, May 5th.
On average, analysts expect that AxoGen will report full year sales of $125.55 million for the current fiscal year, with estimates ranging from $124.00 million to $127.10 million. For the next year, analysts expect that the firm will report sales of $144.90 million, with estimates ranging from $141.50 million to $148.30 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Sunday, February 21st. The medical equipment provider reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.08. AxoGen had a negative return on equity of 19.83% and a negative net margin of 22.98%. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $32.40 million.
A number of institutional investors and hedge funds have recently bought and sold shares of AXGN. Janus Henderson Group PLC boosted its stake in AxoGen by 16.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,505,232 shares of the medical equipment provider’s stock worth $26,944,000 after buying an additional 208,820 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in AxoGen by 110.7% during the fourth quarter. JPMorgan Chase & Co. now owns 287,928 shares of the medical equipment provider’s stock worth $5,155,000 after buying an additional 151,266 shares in the last quarter. BlackRock Inc. boosted its stake in AxoGen by 5.0% during the fourth quarter. BlackRock Inc. now owns 3,006,028 shares of the medical equipment provider’s stock worth $53,807,000 after buying an additional 142,239 shares in the last quarter. William Blair Investment Management LLC boosted its stake in AxoGen by 6.5% during the fourth quarter. William Blair Investment Management LLC now owns 1,351,771 shares of the medical equipment provider’s stock worth $24,197,000 after buying an additional 82,686 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its stake in AxoGen by 7.5% during the fourth quarter. Baillie Gifford & Co. now owns 1,161,752 shares of the medical equipment provider’s stock worth $20,795,000 after buying an additional 81,068 shares in the last quarter. Hedge funds and other institutional investors own 78.38% of the company’s stock.
AXGN stock traded down $0.71 during midday trading on Friday, hitting $18.64. 5,826 shares of the company traded hands, compared to its average volume of 238,005. AxoGen has a twelve month low of $7.65 and a twelve month high of $22.89. The company has a quick ratio of 6.81, a current ratio of 7.45 and a debt-to-equity ratio of 0.42. The business has a 50 day simple moving average of $19.59 and a 200-day simple moving average of $17.85. The stock has a market capitalization of $759.99 million, a price-to-earnings ratio of -30.71 and a beta of 0.71.
AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Recommended Story: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.